These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2897118)

  • 1. Anticataleptic effect of taurine: interaction with antiparkinsonian agents.
    Zebrowska-Lupina I; Porowska A
    Pol J Pharmacol Pharm; 1987; 39(4):329-35. PubMed ID: 2897118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of antidepressants with antiparkinsonian agents in rats.
    Zebrowska-Lupina I; Porowska A; Pietrasiewicz T
    Pol J Pharmacol Pharm; 1985; 37(6):865-74. PubMed ID: 3832020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of antihistaminics on cataleptogenic action of analgesics and haloperidol.
    Malec D; Langwiński R
    Pol J Pharmacol Pharm; 1983; 35(4):293-300. PubMed ID: 6141553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of serotonergic agents on neuroleptic induced catalepsy in rats.
    Rao SG; Hrishikeshavan HJ; Guruswami MN
    Funct Neurol; 1990; 5(4):353-60. PubMed ID: 1982664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
    Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
    Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats.
    Kleven MS; Barret-Grévoz C; Bruins Slot L; Newman-Tancredi A
    Neuropharmacology; 2005 Aug; 49(2):135-43. PubMed ID: 15996562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of cataleptogenic effects of neuroleptics by prostaglandins.
    Herman ZS; Słomińska-Zurek J; Kryk A; Kmieciak-Kołada K
    Pol J Pharmacol Pharm; 1978; 30(5):639-46. PubMed ID: 35782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The action of neuroleptics on different types of catalepsy in rats with a genetic predisposition to catatonic reactions].
    Kolpakov VG; Nikulina EM; Alekhina TA; Gevorgian MM
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1995; 45(2):388-94. PubMed ID: 7597835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of M3-choline receptor blockade on the ability of muscarinic antagonists to prevent catalepsy induced by haloperidol in rats].
    Kosmachev AB; Beliaev VA; Khrabrova AV; Libman NM; Dolgo-Saburov VB
    Eksp Klin Farmakol; 2001; 64(4):10-2. PubMed ID: 11589099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haloperidol-induced catalepsy is influenced by calcium channel antagonists.
    Biała G
    Acta Pol Pharm; 2000; 57(3):233-7. PubMed ID: 11143713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of WA-335, a factor which blocks serotonin receptors, on neuroleptic-induced catalepsy.
    Maj J; Sowińska H; Baran L
    Arch Immunol Ther Exp (Warsz); 1976; 24(2):197-203. PubMed ID: 945050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of selective m-cholinopositive substances on the antiparkinson activity of atropine].
    Khrabrova AV; Kosmachev AB; Titkova TA; Chigarev AG
    Eksp Klin Farmakol; 1999; 62(4):7-8. PubMed ID: 10513326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of antineoplaston A5 on particular subtypes of central dopaminergic receptors.
    Juszkiewicz M; Chodkowska A; Burzynski SR; Mlynarczyk M; Kleinrok Z
    Drugs Exp Clin Res; 1995; 21(4):153-6. PubMed ID: 8529528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Catalepsy produced by long-acting neuroleptics, fluphenazine enanthate and fluphenazine decanoate, in mice.
    Yamada K; Furukawa T
    Pharmacology; 1982; 24(3):147-55. PubMed ID: 7200248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of the genotype in the cataleptogenic effect of neuroleptics].
    Skrinskaia IuA; Nikulina EM; Popova NK
    Eksp Klin Farmakol; 1992; 55(6):7-9. PubMed ID: 1363957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.
    Steece-Collier K; Chambers LK; Jaw-Tsai SS; Menniti FS; Greenamyre JT
    Exp Neurol; 2000 May; 163(1):239-43. PubMed ID: 10785463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat.
    Lipska BK; Jaskiw GE; Braun AR; Weinberger DR
    Biol Psychiatry; 1995 Aug; 38(4):255-62. PubMed ID: 8547448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats.
    Ossowska K; Konieczny J; Wolfarth S; Pilc A
    Neuropharmacology; 2005 Sep; 49(4):447-55. PubMed ID: 15919101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens.
    Ohno Y; Shimizu S; Imaki J; Ishihara S; Sofue N; Sasa M; Kawai Y
    Neuropharmacology; 2008 Oct; 55(5):717-23. PubMed ID: 18585397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central action of narcotic analgesics. VIII. The effect of dopaminergic stimulants on the action of analgesics in rats.
    Malec D; Langwiński R
    Pol J Pharmacol Pharm; 1981 Oct; 33(3):273-82. PubMed ID: 6119681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.